Madhuri Hegde

Madhuri Hegde

Auto-generated profile, based on publicly available information

Madhuri Hegde

Revvity, Waltham, MA, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2018 in Human Mutation
Verified
Journal Article
Closed access
PDF file
EREdgar A. Rivera‐Muñoz
Edgar A. Rivera‐Muñoz
LMLaura Vogel Milko
Laura Vogel Milko
SHSteven Harrison
Steven Harrison
DADanielle R. Azzariti
Danielle R. Azzariti
CKC. Lisa Kurtz
C. Lisa Kurtz
JBJonathan S. Berg
Jonathan S. Berg

5 November 2020 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
SCSamya Chakravorty
Samya Chakravorty
BNBabi Ramesh Reddy Nallamilli
Babi Ramesh Reddy Nallamilli
SKSatish Vasant Khadilkar
Satish Vasant Khadilkar
MSMadhu Bala Singla
Madhu Bala Singla
ABAshish Bhutada
Ashish Bhutada
MHMadhuri Hegde
Madhuri Hegde
Objective: Inherited myopathies comprise more than 200 different individually rare disease-subtypes, but when combined together they have a high prevalence of 1 in 6,000 individuals across the world. Our goal was to determine for the first time the clinical- and gene-variant spectrum of genetic myopathies in a substantial cohort study of the Indian subcontinent. Methods: In this cohort study, we performed the first large clinical exome sequencing (ES) study with phenotype correlation on 207 clinically well-characterized inherited myopathy-suspected patients from the Indian subcontinent with diverse ethnicities. Results: Clinical-correlation driven definitive molecular diagnosis was established in 49% (101 cases; 95% CI, 42–56%) of patients with the major contributing pathogenicity in either of three genes, GNE (28%; GNE-myopathy), DYSF (25%; Dysferlinopathy), and CAPN3 (19%; Calpainopathy). We identified 65 variant alleles comprising 37 unique variants in these three major genes. Seventy-eight percent of the DYSF patients were homozygous for the detected pathogenic variant, suggesting the need for carrier-testing for autosomal-recessive disorders like Dysferlinopathy that are common in India. We describe the observed clinical spectrum of myopathies including uncommon and rare subtypes in India: Sarcoglycanopathies (SGCA/B/D/G), Collagenopathy (COL6A1/2/3), Anoctaminopathy (ANO5), telethoninopathy (TCAP), Pompe-disease (GAA), Myoadenylate-deaminase-deficiency-myopathy (AMPD1), myotilinopathy (MYOT), laminopathy (LMNA), HSP40-proteinopathy (DNAJB6), Emery-Dreifuss-muscular-dystrophy (EMD), Filaminopathy (FLNC), TRIM32-proteinopathy (TRIM32), POMT1-proteinopathy (POMT1), and Merosin-deficiency-congenital-muscular-dystrophy-type-1 (LAMA2). Thirteen patients harbored pathogenic variants in >1 gene and had unusual clinical features suggesting a possible role of synergistic-heterozygosity/digenic-contribution to disease presentation and progression. Conclusions: Application of clinically correlated ES to myopathy diagnosis has improved our understanding of the clinical and genetic spectrum of different subtypes and their overlaps in Indian patients. This, in turn, will enhance the global gene-variant-disease databases by including data from developing countries/continents for more efficient clinically driven molecular diagnostics.

28 February 2021 in Human Mutation
Verified
Journal Article
Closed access
PDF file
BNBabi R. R. Nallamilli
Babi R. R. Nallamilli
ACAlka Chaubey
Alka Chaubey
CVC. A. Valencia
C. A. Valencia
LSLeah Stansberry
Leah Stansberry
ABAndrea M. Behlmann
Andrea M. Behlmann
MHMadhuri Hegde
Madhuri Hegde

26 February 2023 in Clinical Genetics
Verified
Journal Article
Closed access
HAHuda B. Al‐Kouatly
Huda B. Al‐Kouatly
KSKavya Shivashankar
Kavya Shivashankar
MMMatthew H. Mossayebi
Matthew H. Mossayebi
MMMona Makhamreh
Mona Makhamreh
ECElizabeth Critchlow
Elizabeth Critchlow
SBSeth I. Berger
Seth I. Berger

12 October 2023 in Genetics in Medicine
Verified
Journal Article
Closed access
FGFen Guo
Fen Guo
RLRuby Liu
Ruby Liu
YPYinghong Pan
Yinghong Pan
CCChristin Collins
Christin Collins
LBLora Bean
Lora Bean
MHMadhuri Hegde
Madhuri Hegde

19 May 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
NSNikhil S. Sahajpal
Nikhil S. Sahajpal
AMAshis Kumar Mondal
Ashis Kumar Mondal
SASudha Ananth
Sudha Ananth
ANAllan Njau
Allan Njau
Pankaj AhluwaliaPankaj Ahluwalia
Pankaj Ahluwalia
RKRavindra Kolhe
Ravindra Kolhe
Objectives: Limitations of widespread current COVID-19 diagnostic testing exist in both the pre-analytical and analytical stages. To alleviate these limitations, we developed a universal saliva processing protocol (SalivaSTAT) that would enable an extraction-free RT-PCR test using commercially available RT-PCR kits. Methods: We optimized saliva collection devices, heat-shock treatment, and homogenization. Saliva samples (879) previously tested using the FDA-EUA method were reevaluated with the optimized SalivaSTAT protocol using two widely available commercial RT-PCR kits. A five-sample pooling strategy was evaluated as per FDA guidelines. Results: Saliva collection (done without any media) showed performance comparable to that of the FDA-EUA method. The SalivaSTAT protocol was optimized by incubating saliva samples at 95 °C for 30-min and homogenization, followed by RT-PCR assay. The clinical sample evaluation of 630 saliva samples using the SalivaSTAT protocol with PerkinElmer (600-samples) and CDC (30-samples) RT-PCR assay achieved positive (PPA) and negative percent agreements (NPAs) of 95.0% and 100%, respectively. The LoD was established as ~60–180 copies/mL by absolute quantification. Furthermore, a five-sample-pooling evaluation using 250 saliva samples achieved a PPA and NPA of 92% and 100%, respectively. Conclusion: We have optimized an extraction-free RT-PCR assay for saliva samples that demonstrates comparable performance to FDA-EUA assay (Extraction and RT-PCR).